BACKGROUND: Meningiomas are known to recur frequently, and their longterm management remains controversial. Previous studies indicate that progesterone and its receptors can play a role in the recurrence of meningiomas, but the correlation between the presence of these receptors and patients' outcome is unclear. AIM: To conduct a retrospective analysis to investigate the prognostic relevance of progesterone receptor (PR) expression in meningiomas. METHODS: Five hundred and eighty eight meningiomas operated on over a period of 10 years were examined immunohistochemically to determine the PR status using monoclonal antibodies. Several factors including recurrence (mean follow up of 65 month), sex, tumour tissue consistency, location, vascularity, and en plaque appearance were analysed. RESULTS: PR status showed comparable values for men and women. World Health Organisation (WHO) grade II and III tumours had significantly fewer receptors than benign meningiomas. There was no significant correlation between PR status and recurrence rates in WHO grade I totally removed meningiomas. However, a combination of PR status and proliferation indices was shown to predict recurrence reliably. CONCLUSIONS: Together with routine histological evaluation, PR status can help to describe the biological behaviour of meningiomas. Only a combination of clinical and biological features can describe the behaviour of meningiomas, predict their recurrence, and help to devise more effective follow up strategies.
BACKGROUND:Meningiomas are known to recur frequently, and their longterm management remains controversial. Previous studies indicate that progesterone and its receptors can play a role in the recurrence of meningiomas, but the correlation between the presence of these receptors and patients' outcome is unclear. AIM: To conduct a retrospective analysis to investigate the prognostic relevance of progesterone receptor (PR) expression in meningiomas. METHODS: Five hundred and eighty eight meningiomas operated on over a period of 10 years were examined immunohistochemically to determine the PR status using monoclonal antibodies. Several factors including recurrence (mean follow up of 65 month), sex, tumour tissue consistency, location, vascularity, and en plaque appearance were analysed. RESULTS:PR status showed comparable values for men and women. World Health Organisation (WHO) grade II and III tumours had significantly fewer receptors than benign meningiomas. There was no significant correlation between PR status and recurrence rates in WHO grade I totally removed meningiomas. However, a combination of PR status and proliferation indices was shown to predict recurrence reliably. CONCLUSIONS: Together with routine histological evaluation, PR status can help to describe the biological behaviour of meningiomas. Only a combination of clinical and biological features can describe the behaviour of meningiomas, predict their recurrence, and help to devise more effective follow up strategies.
Authors: M A Blankenstein; F M Verheijen; J M Jacobs; T H Donker; M W van Duijnhoven; J H Thijssen Journal: Steroids Date: 2000 Oct-Nov Impact factor: 2.668
Authors: F M Verheijen; G H Donker; C Sales Viera; M Sprong; H M Jacobs; G Blaauw; J H H Thijssen; M A Blankenstein Journal: J Neurooncol Date: 2002-01 Impact factor: 4.130
Authors: H M Strik; I Strobelt; B Pietsch-Breitfeld; J R Iglesias-Rozas; B Will; Richard Meyermann Journal: In Vivo Date: 2002 Jul-Aug Impact factor: 2.155
Authors: S K Yrjänä; H Tuominen; A Karttunen; N Lähdesluoma; E Heikkinen; J Koivukangas Journal: AJNR Am J Neuroradiol Date: 2006 Nov-Dec Impact factor: 3.825
Authors: Tessa A Harland; Jacob L Freeman; Monica Davern; D Jay McCracken; Emma C Celano; Kevin Lillehei; Jeffrey J Olson; D Ryan Ormond Journal: J Neurooncol Date: 2017-10-28 Impact factor: 4.130
Authors: Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo Journal: J Neurooncol Date: 2011-01-04 Impact factor: 4.130
Authors: Angel Maillo; Alberto Orfao; Ana B Espinosa; José María Sayagués; Marta Merino; Pablo Sousa; Monica Lara; María Dolores Tabernero Journal: Neuro Oncol Date: 2007-08-17 Impact factor: 12.300